Novartis is set to invest $23 billion in US-based manufacturing and research and development (R&D) over the next five years, ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Swiss pharmaceutical firm Novartis AG plans to invest $23 billion in the US over the next five years to ensure its key drugs ...

Hikma Pharmaceuticals (OTCPK:HKMPF) announced on Thursday that it has acquired the FDA-approved Abbreviated New Drug ...

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Nikki Odum was on vacation with her family when she noticed something unusual — a strange shape under her armpit near her left breast. At 36 years old, this discovery was both unexpected and alarming.

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 ...

Novartis NVS shares ended the last trading session 4% higher at $107.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.